Santhera Pharmaceuticals Holding AG SPHDF
Set alert
At close · Oct 30
- YTD
- +37.08%
- 1 year
- +49.14%
- Open
- 22.85
- Prev close
- 18.30
- Mkt cap
- 280.34M
- Vol
- 100
- Avg vol
- 10
- EPS
- -2.82
- P/E
- 0.00
More statistics
- Low
- 22.85
- High
- 22.85
News
1 month ago seekingalpha.com
Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2026 Earnings Call Transcript
Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2026 Earnings Call Transcript
2 months ago proactiveinvestors.co.uk
Santhera nears cash break-even as AGAMREE gains traction, Edison says
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare-disease drugmaker, is closing in on a financial turning point, according to research house Edison. In a QuickView note…
6 months ago seekingalpha.com
Santhera Pharmaceuticals Holding AG (SPHDF) Q4 2025 Earnings Call Transcript
Santhera Pharmaceuticals Holding AG (SPHDF) Q4 2025 Earnings Call Transcript
6 months ago proactiveinvestors.com
eBay heads into Q1 earnings with momentum, but macro clouds loom
With eBay Inc (NASDAQ:EBAY, XETRA:EBA) set to report its first-quarter 2026 results on April 29, UBS has bumped its price target on the stock to $110 from...
6 months ago proactiveinvestors.co.uk
Santhera reconfirms cash flow breakeven target as AGAMREE revenues near-double
The Swiss rare disease specialist expects to reach breakeven in the third quarter of 2026 without raising additional funds. Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss…
6 months ago globenewswire.com
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 28, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT.
6 months ago proactiveinvestors.co.uk
Santhera wins backing to extend DMD drug AGAMREE to toddlers as young as two
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare disease specialist, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for…
8 months ago defenseworld.net
Santhera Pharmaceuticals (OTCMKTS:SPHDF) Trading Up 35.4% – What’s Next?
Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF - Get Free Report)'s stock price was up 35.4% during mid-day trading on Tuesday. The company traded as high as $22.04 and last traded at $22.04.…
8 months ago proactiveinvestors.co.uk
Santhera Pharmaceuticals: Delivers life-changing treatment to little fanfare. Soon the numbers will support its progress
November 3, 2025, should have registered as a turning point for Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0). Yet, the date passed with little market fanfare, even though it marked the…
9 months ago proactiveinvestors.com
BlackRock shares jump on Q4 earnings, record $14T assets under management
BlackRock Inc (NYSE:BLK) reported fourth quarter 2025 earnings that exceeded Wall Street expectations and ended the year with a record $14 trillion in...
9 months ago proactiveinvestors.co.uk
Santhera lands key approval for DMD treatment in Switzerland
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) told investors it has received approval from Swissmedic for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy in patients…
9 months ago proactiveinvestors.com
Santhera lands key approval for DMD treatment in Switzerland
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) told investors it has received approval from Swissmedic for AGAMREE® (vamorolone) for the treatment...
9 months ago proactiveinvestors.com
Aritzia shares rise as Q3 earnings top expectations
Aritzia Inc (TSX:ATZ) shares moved higher as it reported fiscal third quarter earnings that topped analyst expectations, driven by growth in both its retail...
9 months ago proactiveinvestors.co.uk
Santhera shares jump after $205 million Asia-Pacific licensing deal
Shares in Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) rose 7.4% to CHF 13.14 after the group struck a licensing deal worth up to $205 million plus royalties for its Duchenne muscular dystrophy…
9 months ago proactiveinvestors.com
Santhera shares jump after $205 million Asia-Pacific licensing deal
Shares in Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) rose 7.4% to CHF 13.14 after the group struck a licensing deal worth up to $205 million plus...
9 months ago proactiveinvestors.co.uk
Santhera Pharma strikes $205 million Asia-Pacific deal for Duchenne muscular dystrophy drug
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) has signed a licensing deal worth up to $205 million plus royalties for its Duchenne muscular dystrophy treatment AGAMREE, handing rights in key…
9 months ago proactiveinvestors.com
Santhera Pharma strikes $205 million Asia-Pacific deal for Duchenne muscular dystrophy drug
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) has signed a licensing deal worth up to $205 million plus royalties for its Duchenne muscular dystrophy...
1 year ago seekingalpha.com
Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2025 Earnings Call Transcript
Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) Q2 2025 Earnings Call September 23, 2025 8:00 AM EDT Company Participants Catherine Isted - Chief Financial Officer Shabir Hasham - Chief Medical…